← back to search

Caroline M. Tanner

San Francisco VA Medical Center · US
Area of research
Neurology · Cellular and Molecular Neuroscience
Research interest
Research interests include Parkinson's Disease Mechanisms and Treatments, Neurological disorders and treatments, Nuclear Receptors and Signaling, and Parkinson's Disease and Spinal Disorders.
h-index
97
citations
43,557
works
454
NIH funding
primary concept
Medicine
email

Recent publications

Environmental toxicants and Parkinson's disease: recent evidence, risks, and prevention opportunities
The Lancet Neurology 2025cited by 19position: lastdoi
<i>LRRK2</i> -associated parkinsonism with and without <i>in vivo</i> evidence of alpha-synuclein aggregates: longitudinal clinical and biomarker characterization
Brain Communications 2025cited by 15position: middledoi
Neuronal α‐Synuclein Disease Stage Progression over 5 Years
Movement Disorders 2025cited by 12position: middledoi
The epidemiology of Parkinson's disease
The Lancet 2024cited by 784position: lastdoi
A biological definition of neuronal α-synuclein disease: towards an integrated staging system for research
The Lancet Neurology 2024cited by 540position: middledoi
Epidemiology of Parkinson’s Disease: An Update
Current Neurology and Neuroscience Reports 2024cited by 59position: middledoi
Occupational Pesticide Exposure in Parkinson’s Disease Related to <i>GBA</i> and <i>LRRK2</i> Variants
Journal of Parkinson s Disease 2024cited by 17position: middledoi
Staged Screening Identifies People with Biomarkers Related to Neuronal Alpha‐Synuclein Disease
Annals of Neurology 2024cited by 13position: middledoi
Twelve Years of Drug Prioritization to Help Accelerate Disease Modification Trials in Parkinson’s Disease: The International Linked Clinical Trials Initiative
Journal of Parkinson s Disease 2024cited by 12position: middledoi
Eleven Years of Change: Disease Progression in Biomarker-Defined Sporadic Parkinson’s Disease
medRxiv 2024cited by 1position: middledoi
Assessment of heterogeneity among participants in the Parkinson's Progression Markers Initiative cohort using α-synuclein seed amplification: a cross-sectional study
The Lancet Neurology 2023cited by 671position: middledoi
Proposal for a Biologic Staging System of Parkinson’s Disease
Journal of Parkinson s Disease 2023cited by 84position: middledoi
Risk of Parkinson Disease Among Service Members at Marine Corps Base Camp Lejeune
JAMA Neurology 2023cited by 76position: lastdoi
Trichloroethylene: An Invisible Cause of Parkinson’s Disease?
Journal of Parkinson s Disease 2023cited by 68position: middledoi
Parkinson’s Progression Markers Initiative: A Milestone-Based Strategy to Monitor Parkinson’s Disease Progression
Journal of Parkinson s Disease 2023cited by 63position: middledoi
LRRK2 and GBA1 variant carriers have higher urinary bis(monacylglycerol) phosphate concentrations in PPMI cohorts
npj Parkinson s Disease 2023cited by 41position: middledoi
American Football Play and Parkinson Disease Among Men
JAMA Network Open 2023cited by 26position: middledoi
Prevalence and Incidence of Parkinson's Disease in Latin America: A Meta‐Analysis
Movement Disorders 2023cited by 25position: middledoi
Study in Parkinson’s disease of exercise phase 3 (SPARX3): study protocol for a randomized controlled trial
Trials 2022cited by 34position: middledoi
Longitudinal clinical and biomarker characteristics of non-manifesting LRRK2 G2019S carriers in the PPMI cohort
npj Parkinson s Disease 2022cited by 18position: middledoi
Remote smartphone monitoring of Parkinson’s disease and individual response to therapy
Nature Biotechnology 2021cited by 138position: middledoi
Genomewide Association Studies of <scp> <i>LRRK2</i> </scp> Modifiers of Parkinson's Disease
Annals of Neurology 2021cited by 49position: middledoi
Prevalence of parkinsonism and Parkinson disease in urban and rural populations from Latin America: A community based study
The Lancet Regional Health - Americas 2021cited by 42position: middledoi
Longitudinal Analysis of Multiple Neurotransmitter Metabolites in Cerebrospinal Fluid in Early Parkinson's Disease
Movement Disorders 2021cited by 39position: middledoi
Sex-Related Longitudinal Change of Motor, Non-Motor, and Biological Features in Early Parkinson’s Disease
Journal of Parkinson s Disease 2021cited by 33position: middledoi
The TOPAZ study: a home-based trial of zoledronic acid to prevent fractures in neurodegenerative parkinsonism
npj Parkinson s Disease 2021cited by 25position: firstdoi
Current and projected future economic burden of Parkinson’s disease in the U.S.
npj Parkinson s Disease 2020cited by 630position: middledoi
Validation of Serum Neurofilament Light Chain as a Biomarker of Parkinson's Disease Progression
Movement Disorders 2020cited by 196position: middledoi
The Effect of the COVID-19 Pandemic on People with Parkinson’s Disease
Journal of Parkinson s Disease 2020cited by 178position: lastdoi
Fox Insight collects online, longitudinal patient-reported outcomes and genetic data on Parkinson’s disease
Scientific Data 2020cited by 110position: lastdoi

Grants

No grants ingested yet.

Frequent collaborators

Kenneth Marek · Montreal Neurological Institute and Hospital16 papers (2012–2024)Samuel M. Goldman · University of California, San Francisco15 papers (2014–2025)Lana M. Chahine · University of Pittsburgh13 papers (2017–2025)Tanya Simuni · Northwestern University12 papers (2016–2025)Chelsea Caspell‐Garcia · University of Iowa11 papers (2016–2024)Andrew Siderowf · University of Pennsylvania11 papers (2013–2025)Christopher S. Coffey · University of Iowa9 papers (2017–2025)Connie Marras · University Health Network9 papers (2014–2024)Daniel Weintraub · California University of Pennsylvania8 papers (2017–2025)Brit Mollenhauer · Short and Associates (United States)7 papers (2017–2023)E. Ray Dorsey · Global Brain Health Institute7 papers (2014–2025)Robert A. Hauser · University of South Florida7 papers (2014–2020)Anthony E. Lang · Istituti di Ricovero e Cura a Carattere Scientifico6 papers (2012–2020)Michael C. Brumm · University of Iowa6 papers (2023–2025)Ethan Brown · University of California, San Francisco6 papers (2020–2024)Monica Korell · University of California, San Francisco6 papers (2014–2024)Cheryl Meng · University of California, San Francisco5 papers (2014–2024)Karl Kieburtz · University of Rochester Medical Center5 papers (2017–2024)J. William Langston · Palo Alto University5 papers (2012–2020)Samantha J. Hutten · University of Iowa5 papers (2020–2023)